Allergan, Inc.-Product Pipeline Review-2015

Allergan, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06889CDB
  • |
  • Pages: 83
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Allergan, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Allergan, Inc.-Product Pipeline Review-2015', provides an overview of the Allergan, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Allergan, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Allergan, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Allergan, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Allergan, Inc.'s pipeline products

Reasons To Buy

Evaluate Allergan, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Allergan, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Allergan, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Allergan, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Allergan, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Allergan, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Allergan, Inc. Snapshot 7

Allergan, Inc. Overview 7

Key Information 7

Key Facts 7

Allergan, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Allergan, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Combination Treatment Modalities 13

Pipeline Products-Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Pipeline Products-Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

Allergan, Inc.-Pipeline Products Glance 18

Allergan, Inc.-Late Stage Pipeline Products 18

Filing rejected/Withdrawn Products/Combination Treatment Modalities 18

Phase III Products/Combination Treatment Modalities 19

Allergan, Inc.-Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Allergan, Inc.-Early Stage Pipeline Products 22

Preclinical Products/Combination Treatment Modalities 22

Discovery Products/Combination Treatment Modalities 23

Allergan, Inc.-Drug Profiles 24

dihydroergotamine mesylate 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Aczone X 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

AGN-229666 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

bimatoprost 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

bimatoprost SR 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

cyclosporine 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

desmopressin acetate 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

onabotulinumtoxin A 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

oxymetazoline hydrochloride 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

(bimatoprost + brimonidine tartrate) 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

abicipar pegol 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

AGN-195263 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

beclomethasone dipropionate 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

brimonidine tartrate implant 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

lidocaine 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

senrebotase 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

AGN-223575 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

AGN-151200 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Drug to Agonize D2/D3 Receptors for Parkinson's Disease 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Drug to Agonize GABA Receptor for Epilepsy 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Drug to Inhibit Tyrosine Kinase for AMD 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Small Molecule for Glaucoma 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Neurotoxin Program 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Allergan, Inc.-Pipeline Analysis 52

Allergan, Inc.-Pipeline Products by Target 52

Allergan, Inc.-Pipeline Products by Route of Administration 54

Allergan, Inc.-Pipeline Products by Molecule Type 55

Allergan, Inc.-Pipeline Products by Mechanism of Action 56

Allergan, Inc.-Recent Pipeline Updates 57

Allergan, Inc.-Dormant Projects 70

Allergan, Inc.-Discontinued Pipeline Products 71

Discontinued Pipeline Product Profiles 71

budesonide 71

dexamethasone 71

memantine hydrochloride 71

onabotulinumtoxin A 71

Allergan, Inc.-Company Statement 73

Allergan, Inc.-Locations And Subsidiaries 77

Head Office 77

Other Locations & Subsidiaries 77

Allergan, Inc.-Key Manufacturing Facilities 81

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

Allergan, Inc., Key Information 7

Allergan, Inc., Key Facts 7

Allergan, Inc.-Pipeline by Indication, 2015 9

Allergan, Inc.-Pipeline by Stage of Development, 2015 11

Allergan, Inc.-Monotherapy Products in Pipeline, 2015 12

Allergan, Inc.-Combination Treatment Modalities in Pipeline, 2015 13

Allergan, Inc.-Partnered Products in Pipeline, 2015 14

Allergan, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 15

Allergan, Inc.-Out-Licensed Products in Pipeline, 2015 16

Allergan, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 17

Allergan, Inc.-Filing rejected/Withdrawn, 2015 18

Allergan, Inc.-Phase III, 2015 19

Allergan, Inc.-Phase II, 2015 20

Allergan, Inc.-Phase I, 2015 21

Allergan, Inc.-Preclinical, 2015 22

Allergan, Inc.-Discovery, 2015 23

Allergan, Inc.-Pipeline by Target, 2015 53

Allergan, Inc.-Pipeline by Route of Administration, 2015 54

Allergan, Inc.-Pipeline by Molecule Type, 2015 55

Allergan, Inc.-Pipeline Products by Mechanism of Action, 2015 56

Allergan, Inc.-Recent Pipeline Updates, 2015 57

Allergan, Inc.-Dormant Developmental Projects,2015 70

Allergan, Inc.-Discontinued Pipeline Products, 2015 71

Allergan, Inc., Subsidiaries 77

Allergan, Inc., Key Manufacturing Facilities 81

List of Figures

Allergan, Inc.-Pipeline by Top 10 Indication, 2015 9

Allergan, Inc.-Pipeline by Stage of Development, 2015 11

Allergan, Inc.-Monotherapy Products in Pipeline, 2015 12

Allergan, Inc.-Partnered Products in Pipeline, 2015 14

Allergan, Inc.-Pipeline by Top 10 Target, 2015 52

Allergan, Inc.-Pipeline by Top 10 Route of Administration, 2015 54

Allergan, Inc.-Pipeline by Top 10 Molecule Type, 2015 55

Allergan, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Allergan, Inc.; Allergan, Inc. - Key Therapeutics; Allergan, Inc. - Pipeline Overview and Promising Molecules; Allergan, Inc. - News; Allergan, Inc. - Latest Updates; Allergan, Inc. - Pipeline; Allergan, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 100395
Site License
USD 3000 INR 200790
Corporate User License
USD 4500 INR 301185



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]